title: Rapid and highly efficient generation of induced pluripotent stem cells from human umbilical vein endothelial cells.
abstract: The ability to induce somatic cells to pluripotency by ectopic expression of defined transcription factors (e.g. KLF-4, OCT4, SOX2, c-MYC, or KOSM) has transformed the future of regenerative medicine. Here we report somatic cell reprogramming of human umbilical vein endothelial cells (HUVECs), yielding induced pluripotent stem (iPS) cells with the fastest kinetics, and one of the highest reprogramming efficiencies for a human somatic cell to date. HUVEC-derived iPS (Huv-iPS) cell colonies appeared as early as 6 days after a single KOSM infection, and were generated with a 2.5-3% reprogramming efficiency. Furthermore, when HUVEC reprogramming was performed under hypoxic conditions in the presence of a TGF-beta family signaling inhibitor, colony formation increased an additional ∼2.5-fold over standard conditions. Huv-iPS cells were indistinguishable from human embryonic stem (ES) cells with regards to morphology, pluripotent marker expression, and their ability to generate all embryonic germ layers in vitro and in vivo. The high efficiency and rapid kinetics of Huv-iPS cell formation, coupled with the ease by which HUVECs can be collected, expanded and stored, make these cells an attractive somatic source for therapeutic application, and for studying the reprogramming process.
authors: Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, California, United States of America.
authors: Athanasia D
authors: AD
authors: Panopoulos
authors: Sergio
authors: S
authors: Ruiz
authors: Fei
authors: F
authors: Yi
authors: Aída
authors: A
authors: Herrerías
authors: Erika M
authors: EM
authors: Batchelder
authors: Juan Carlos
authors: JC
authors: Izpisua Belmonte
references: Cell Stem Cell. 2010 Jul 2;7(1):20-4
references: 20621045
references: Nature. 2010 Jun 10;465(7299):704-12
references: 20535199
references: Cell. 2006 Aug 25;126(4):663-76
references: 16904174
references: Nat Methods. 2006 Aug;3(8):637-46
references: 16862139
references: Cell Stem Cell. 2009 Oct 2;5(4):353-7
references: 19796614
references: Nat Biotechnol. 2008 Nov;26(11):1276-84
references: 18931654
references: Nat Biotechnol. 2006 Feb;24(2):185-7
references: 16388305
references: Lancet. 2005 Dec 10;366(9502):2019-25
references: 16338451
references: Nat Protoc. 2007;2(3):481-5
references: 17406610
references: Cell Stem Cell. 2009 Oct 2;5(4):434-41
references: 19796623
references: PLoS One. 2010 Dec 09;5(12):e15526
references: 21170306
references: Science. 1998 Nov 6;282(5391):1145-7
references: 9804556
references: Curr Biol. 2009 Nov 3;19(20):1718-23
references: 19765992
references: Nat Biotechnol. 2009 Aug;27(8):743-5
references: 19590502
references: Nat Biotechnol. 2008 Jul;26(7):739-40
references: 18612291
references: Cell Stem Cell. 2009 Sep 4;5(3):237-41
references: 19716359
references: Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1905-7
references: 20689077
references: Cell Stem Cell. 2009 Nov 6;5(5):491-503
references: 19818703
references: Cell Stem Cell. 2010 Dec 3;7(6):651-5
references: 21112560
references: Cell Cycle. 2010 Mar 1;9(5):937-46
references: 20160486
references: Cell. 2009 Apr 3;137(1):13-7
references: 19345179
references: Cell. 2007 Nov 30;131(5):861-72
references: 18035408
references: Cell Stem Cell. 2008 Dec 4;3(6):595-605
references: 19041776
references: Nature. 2011 Apr 14;472(7342):221-5
references: 21346760
references: Cell Stem Cell. 2010 Jul 2;7(1):11-4
references: 20621043
references: Science. 2007 Dec 21;318(5858):1917-20
references: 18029452
references: Cell Stem Cell. 2010 Jul 2;7(1):15-9
references: 20621044